Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.49 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.49 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GJA1 | P17302 | 1/20 | 0.45 |
| ▸ | GJB2 | P29033 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | AMY2A | P04746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6900928 | 1.00 | MEN1 (0.50) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL2139671 | 1.00 | MEN1 (0.50) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL3188633 | 1.00 | MEN1 (0.50) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL1389240 | 1.00 | MEN1 (0.50) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL15136505 | 0.97 | LGALS8 (0.53) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL16004719 | 0.88 | MEN1 (0.50) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL7121167 | 0.88 | MEN1 (0.50) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL5971913 | 0.88 | MEN1 (0.50) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL15844865 | 0.87 | AMY1A (0.52) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL11776786 | 0.85 | LMNA (0.55) | MEN1KMT2AGJA1GJB2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278268-B2 | administering peroxisome proliferator-activated receptor agonists (PPAR) and sodium glucose co-transporters (SGLTs) inhibitors for the treatment of diabetes and Syndrome X | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-10-02 | — | — | US | claimed |
| EP-1392326-B1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | ORTHO MCNEIL JANSSEN PHARM (US) | 2009-09-09 | — | — | EP | claimed |
| US-20090075864-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | BUSSOLARI JACQUELINE C | 2009-03-19 | — | — | US | claimed |
| EP-1381361-B1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND PPAR MODULATORS | ORTHO MCNEIL JANSSEN PHARM (US) | 2009-02-25 | — | — | EP | claimed |
| US-20080096802-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND PPAR MODULATORS | BUSSOLARI JACQUELINE C | 2008-04-24 | — | — | US | claimed |
| US-6838442-B2 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-01-04 | — | — | US | claimed |
| CN-1511038-A | Combination therepy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators | ����-������ҩƷ��˾ | 2004-07-07 | — | — | CN | claimed |
| EP-1392326-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | Ortho McNeil Pharmaceutical, Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| EP-1381361-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND PPAR MODULATORS | Ortho McNeil Pharmaceutical, Inc. (US) | 2004-01-21 | — | — | EP | claimed |
| US-20030199557-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | BUSSOLARI JACQUELINE C (US) | 2003-10-23 | — | — | US | claimed |
| US-20030195235-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators | BUSSOLARI JACQUELINE C (US) | 2003-10-16 | — | — | US | claimed |
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-03-20 | — | — | US | claimed |
| US-20030045553-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | ORTHO-MCNEIL PHARMACEUITCAL, INC. | 2003-03-06 | — | — | US | claimed |
| WO-2002080935-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-17 | — | — | WO | claimed |
| WO-2002080936-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND PPAR MODULATORS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-17 | — | — | WO | claimed |
| EP-0684254-B1 | Propiophenone derivative and a process for preparing the same | TANABE SEIYAKU CO (JP) | 1999-03-24 | — | — | EP | claimed |
| CN-1042637-C | Propiophenone derivative and a process for preparing the same | TANABE SEIYAKU CO (JP) | 1999-03-24 | — | — | CN | claimed |
| US-5830873-A | ANTIDIABETIC AGENT | TANABE SEIYAKU CO., LTD. (JP) | 1998-11-03 | — | — | US | claimed |
| CN-1121925-A | Propiophenone derivative and a process for preparing the same | TANABE SEIYAKU CO (JP) | 1996-05-08 | — | — | CN | claimed |
| EP-0684254-A1 | Propiophenone derivative and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1995-11-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | GPR119, SLC2A4, SLC2A1 | MEN1 4362/4885KMT2A 4456/4885LGALS8 1018/4885 |
| US-20030195235-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators | GPR119, SLC2A4, SLC2A1 | MEN1 4362/4885KMT2A 4456/4885LGALS8 1018/4885 |
| US-20030045553-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | GPR119, SLC2A4, PPARG | MEN1 4733/4885KMT2A 4696/4885LGALS8 2147/4885 |
| US-20090075864-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | GPR119, SLC2A4, SLC2A1 | MEN1 4362/4885KMT2A 4456/4885LGALS8 1018/4885 |
| US-20030199557-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | GPR119, SLC2A4, PPARG | MEN1 4733/4885KMT2A 4696/4885LGALS8 2147/4885 |
| US-20080096802-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND PPAR MODULATORS | GPR119, SLC2A4, PPARG | MEN1 4733/4885KMT2A 4696/4885LGALS8 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.